Osborne Clarke in Amsterdam advised DSM Venturing, Van Herk Ventures, I2S, Limburgs Instituut voor Ontwikkeling en Financiering and Limburg Ventures in the sale of Isobionics to BASF. Isobionics is an innovation leader in biotechnology which is serving the global market for natural flavours and fragrances, with a focus on citrus oil components such as nootkatone and valencene.
The Osborne Clarke in Amsterdam team was co-led by Partners Cristine Brinkman and Herke van Hulst and consisted of Associate Michelle Pagie, Partners Cars Jan van Gool (Civil Law Notary) and Job van der Pol (Tax) and Associate Florien Sanders.
Osborne Clarke’s life science and healthcare sector team has a strong track record of providing highly sophisticated advice to biotech clients on cutting-edge issues, across multiple service lines. They work with blue chip venture capital firms and the biggest pharma and medical devices companies in the market and earlier this year, advised generic pharmaceutical company Actavis UK Limited and Actavis Ireland Limited on its £603m divestment by Teva Pharmaceutical Industries Ltd to Intas Pharmaceuticals Ltd pursuant to commitments given to the EU.